Product Highlight - Shingrix

Recombinant, adjuvant vaccine for herpes zoster prevention
NEWLY EXPANDED INDICATION
• Indicated for adults aged ≥ 50 and ≥ 18 at increased risk of herpes zoster¹
• The only zoster vaccine to demonstrate >90% efficacy^*1
• Recommended by the US CDC as the preferred zoster vaccine²

*In all age groups ≥ 50 years old

References:
1. GSK. SHINGRIX Hong Kong Full Prescribing Information GDS04.
2. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on the Immunization Practices for the use of herpes zoster vaccine. MMWR 2018 Jan:67(3):103-8.